With scientists yet to discover the specific antigen that confers protection from Epstein-Barr virus (EBV), there are currently no prophylactic vaccines available for the diseases it causes, the most well-known of which is infectious mononucleosis but which evidence suggests might also extend to immune disorders, multiple sclerosis and various cancers. This hasn’t stopped companies from trying, and one such player, EBViously Inc., is hedging its bets with a wider net, using as many proteins as possible to mimic the original viral pathogen and its complexity in a vaccine composed of non-infectious virus-like particles.